Literature DB >> 3076997

Chloroquine treatment of falciparum malaria in an area of Kenya of intermediate chloroquine resistance.

A D Brandling-Bennett1, A J Oloo, W M Watkins, D A Boriga, D M Kariuki, W E Collins.   

Abstract

106 children aged 1-10 years who had pure Plasmodium falciparum infections and temperatures greater than or equal to 38 degrees C were treated with chloroquine base, 25 mg/kg body weight. 29% of the infections were sensitive in vivo, 41% recurred within 4 weeks (RI), 26% were RII resistant, and 4% were RII resistant. Rieckmann micro in vitro tests were successful in 64% of isolates obtained from these children; 63% were resistant to chloroquine. In 58 paired isolates obtained before and after treatment, the level of chloroquine sensitivity was lower in the parasites persisting or recurring after treatment. All children except 2 of the 4 with RIII resistance became afebrile an average of 1.4 d after starting treatment and their other symptoms resolved in an average of 1.8 d. By day 28, 57% of the children with RI resistance and 78% of those with RII resistance had recurrence of fever and other symptoms, compared with 19% of children with sensitive infections. No relationship was observed between the clinical or parasitological response and age, nutritional status, haematocrit, splenomegaly, presence of sickle-cell trait, or seropositivity to malaria by enzyme-linked immunosorbent assay. The study demonstrates that, in most children with malaria in an area of intermediate chloroquine resistance, fever and other symptoms resolve at least temporarily when treated with chloroquine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3076997     DOI: 10.1016/0035-9203(88)90009-0

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  6 in total

1.  The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria.

Authors:  P A Winstanley; W M Watkins; C R Newton; C Nevill; E Mberu; P A Warn; C M Waruiru; I N Mwangi; D A Warrell; K Marsh
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

Review 2.  Treatment of malaria--1990.

Authors:  D M Panisko; J S Keystone
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

3.  Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria.

Authors:  E Amukoye; P A Winstanley; W M Watkins; R W Snow; J Hatcher; M Mosobo; E Ngumbao; B Lowe; M Ton; G Minyiri; K Marsh
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

4.  The disposition of amodiaquine in Zambians and Nigerians with malaria.

Authors:  P A Winstanley; O Simooya; J M Kofi-Ekue; O Walker; L A Salako; G Edwards; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

5.  Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain.

Authors:  A Nzila-Mounda; E K Mberu; C H Sibley; C V Plowe; P A Winstanley; W M Watkins
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

6.  Changing Malaria Prevalence on the Kenyan Coast since 1974: Climate, Drugs and Vector Control.

Authors:  Robert W Snow; Eliud Kibuchi; Stella W Karuri; Gilbert Sang; Caroline W Gitonga; Charles Mwandawiro; Philip Bejon; Abdisalan M Noor
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.